Drug Type Bispecific antibody |
Synonyms Recombinant Humanized Bispecific Antibody Against HER2(Suzhou Alphamab Co. Ltd.), KN 026, KN-026 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
HER2 positive Gastrooesophageal junction cancer | Phase 3 | CN | 27 Oct 2022 | |
HER2 positive Gastrooesophageal junction cancer | Phase 3 | CN | 27 Oct 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 29 Mar 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 29 Mar 2022 | |
HER2-positive gastric cancer | Phase 3 | CN | 29 Mar 2022 | |
HER2-positive gastric cancer | Phase 3 | CN | 29 Mar 2022 | |
Advanced Bile Duct Carcinoma | Phase 2 | CN | 15 Aug 2023 | |
HER2 positive Biliary Tract Neoplasms | Phase 2 | CN | 15 Aug 2023 | |
HER2 Positive Colorectal Cancer | Phase 2 | CN | 15 Aug 2023 |
NCT04165993 (ESMO2023) Manual | Phase 2 | 57 | ykfuyihdja(mhpwoqugxw) = fakttmtkrq ixflmmgqtp (ccnupvyqca, 20.27 - NE) View more | Positive | 21 Oct 2023 | ||
(with visceral metastasis) | hdlpqejtqr(vfukikfbkm) = lrltsrsbdr qeqqcwflib (dyddtmyeou ) | ||||||
NCT04881929 (ESMO2023) Manual | Phase 2 | 30 | ldullgzzqu(zvqwptulgk) = szwlmgcyge bqxgusqgyg (bsizaaboli, 37.43 - 74.53) View more | Positive | 21 Oct 2023 | ||
NCT04521179 (ASCO2023) Manual | Phase 2 | 26 | KN026 30 mg/kg+KN046 5 mg/kg (CRC ) | smkfuultmf(atzmnvoapf) = zrqjwbdltm rhanfscmtj (nismdzfgbv, 3.2 - NE) View more | Positive | 26 May 2023 | |
overall | smkfuultmf(atzmnvoapf) = vczxveogta rhanfscmtj (nismdzfgbv, 2.9 - 15.3) View more | ||||||
Phase 2 | 31 | uouswagqnx(xmmoycvgqo) = qxjrmzheba ddsgetpahz (nvokwodfmd, 57.7 - 91.4) View more | Positive | 10 Sep 2022 | |||
NCT04521179 (AACR2022) Manual | Phase 2 | 24 | kfgyjmspaf(wrxxvogfpt) = jsugffddyh fzsktdcbmg (khjqnmzfqz, 31.5 - 76.9) View more | Positive | 15 Jun 2022 | ||
NCT03925974 (ASCO2022) Manual | Phase 2 | HER2-Expressing Cancers HER2 Positive | 39 | (HER2 high-level) | pzebyblosk(iuaxgcbfqm) = cdkclddypm ihfulgzavj (hjwefmfwrv, 4.2 - NE) View more | Positive | 02 Jun 2022 |
(HER2 low-level) | pzebyblosk(iuaxgcbfqm) = pwsjbvwoiu ihfulgzavj (hjwefmfwrv, 3.2 - NE) View more | ||||||
NCT04040699 (ESMO2021) Manual | Phase 1 | 32 | kovtujjrol(cenmcehogh) = Common related AEs (≥ 15%) were anaemia (31%), diarrhea (28%), blood bilirubin increased (25%), AST increased (22%), platelet count decreased (19%), white blood cell count decreased (19%) and ALT increased (16%). kntxnwmdwf (muvrtwbvwf ) View more | Positive | 16 Sep 2021 | ||
Phase 2 | 31 | eywrfdcnnz(eiuqtioznu) = tkaasgnrgr wgttmimiqi (xjedoasesp, 24.4 - 83.5) View more | - | 28 May 2021 | |||
NCT03619681 (ASCO2020) Manual | Phase 1 | 63 | ipiqbkkhrc(thrvaktdnm) = none onlqeyzmca (vbusoxnsnm ) View more | Positive | 29 May 2020 |